Significant Securities Class Action Filed Against Aardvark Therapeutics, Inc. - Key Dates & Details

Aardvark Therapeutics Faces Class Action Lawsuit

Overview of the Situation

Investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) are now facing crucial legal implications as a securities class action has emerged against the biotech firm. This lawsuit primarily concerns misleading safety claims surrounding the drug ARD-101, made by none other than the company's former Chief Operating Officer, Dr. Bryan Jones. The situation unfolds an alarming narrative regarding the company's previous communication with investors and a critical reassessment of its drug's safety profile.

Timeline of Events

It was during an investor conference on May 20, 2025, when Dr. Jones, in a confident manner, proclaimed that ARD-101 had a “[v]ery, very clean [safety] profile.” He further emphasized that the drug had “essentially no adverse events in Phase I,” attempting to build investor confidence. However, the subsequent events contradicted these claims dramatically.

On February 27, 2026, Aardvark announced a premature voluntary pause of the Phase 3 HERO trial due to concerning cardiac observations at therapeutic doses that exceeded targets. Share prices plummeted significantly from that point. By May 15, 2026, the stock closed at just $4.57, representing a staggering loss of approximately 71.4% from the IPO price of $16.00 established during February 2025.

The Nature of Allegations

The class action lawsuit lays out a case against Dr. Jones and the company for allegedly providing materially false and misleading statements regarding ARD-101's safety and tolerability. It contends that these misleading assertions led to inflated expectations of the drug's commercial and clinical viability. The complaint particularly notes that Jones assured that systemic exposure was minimal due to the drug’s design, which purported to limit absorption to just 1% in the bloodstream, a statement that is now under scrutiny.

Legal experts, including Joseph E. Levi, Esq. of Levi & Korsinsky, LLP, express that “Officers who speak to investors about a lead drug's safety profile bear responsibility for the accuracy of those statements.” This sets a serious precedent for corporate accountability.

Legal Proceedings and Next Steps

The lawsuit was filed in the United States District Court for the Southern District of California, backed by the Private Securities Litigation Reform Act. Current AARD investors are encouraged to gather brokerage records that detail their purchase dates and share quantities, essential for assessing eligibility for potential recovery based on their losses.

The deadline for filing as a lead plaintiff is set for October 13, 2026, emphasizing the urgency for stakeholders to act. Notably, even if investors have sold their shares, they may still qualify for recovery if they purchased during the class period.

Potential participants in the class action do not face any upfront cost and can choose to engage on a contingency basis, meaning legal fees are only payable contingent upon a successful outcome in the case.

Conclusion

The Aardvark Therapeutics class action lawsuit is a pivotal moment for investors, emphasizing the necessity for transparency within the biotech industry. The fallout from this situation could have lasting implications for Aardvark as it navigates the legal complications ahead. Stakeholders must remain vigilant and consult with legal experts to safeguard their investments in the biologics sector. The broader implications of this case could reshape how biotech and pharmaceutical companies communicate drug safety profiles to investors in the future.